在厄瓜多尔首次检测到严重急性呼吸综合征冠状病毒2变体B.1.1.529（奥密克戎）
First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador.
作者信息
Carrazco-Montalvo A, Armendáriz-Castillo I, Tello C L, Morales D, Armas-Gonzalez R, Guizado-Herrera D, León-Sosa A, Ramos-Sarmiento D, Fuertes B, Patino L
机构信息
Dirección de Investigación, Desarrollo e Innovación, Instituto Nacional de Investigación en Salud Pública "Leopoldo Izquieta Pérez", Guayaquil, Ecuador.
Coordinación Zonal 9, Instituto Nacional de Investigación en Salud Pública "Leopoldo Izquieta Pérez", Quito, Ecuador.
出版信息
New Microbes New Infect. 2022 Jan;45:100951. doi: 10.1016/j.nmni.2022.100951. Epub 2022 Jan 7.
Abstract
The National Institute of Research and Public Health reported the first local record of the Omicron variant detected in Ecuador. A fully vaccinated subject returned from South Africa with a negative RT-PCR. We present the cumulative frequency of the variants in Ecuador and a phylogenetic analysis of this new Omicron.
摘要
国家公共卫生研究所报告了在厄瓜多尔首次检测到奥密克戎变种的本地记录。一名完全接种疫苗的受试者从南非返回，其逆转录聚合酶链反应（RT-PCR）检测呈阴性。我们展示了厄瓜多尔变种的累积频率以及对这种新奥密克戎变种的系统发育分析。
相似文献
1
First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador.
New Microbes New Infect. 2022 Jan;45:100951. doi: 10.1016/j.nmni.2022.100951. Epub 2022 Jan 7.
2
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
3
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
4
Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022. doi: 10.26355/eurrev_202112_27653.
5
SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues.
Immune Netw. 2021 Dec 23;21(6):e38. doi: 10.4110/in.2021.21.e38. eCollection 2021 Dec.
6
Comparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study.
medRxiv. 2022 Mar 2:2022.02.27.22271090. doi: 10.1101/2022.02.27.22271090.
7
Tracking the Initial Diffusion of SARS-CoV-2 Omicron Variant in Italy by RT-PCR and Comparison with Alpha and Delta Variants Spreading.
Diagnostics (Basel). 2022 Feb 11;12(2):467. doi: 10.3390/diagnostics12020467.
8
Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa.
J Med Virol. 2022 Apr;94(4):1728-1733. doi: 10.1002/jmv.27516. Epub 2021 Dec 27.
9
Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance.
World J Clin Cases. 2022 Jan 7;10(1):1-11. doi: 10.12998/wjcc.v10.i1.1.
10
Multi-branch cooperation on SARS-CoV-2 omicron capture: a case report.
Cas Lek Cesk. 2022 Spring;161(1):24-27.
引用本文的文献
1
Assessment of the COVID-19 pandemic progression in Ecuador through seroprevalence analysis of anti-SARS-CoV-2 IgG/IgM antibodies in blood donors.
Front Cell Infect Microbiol. 2024 Jun 21;14:1373450. doi: 10.3389/fcimb.2024.1373450. eCollection 2024.
2
First sequenced cases of Omicron BA.2 sublineage in Ecuador.
Virus Res. 2023 Sep;334:199169. doi: 10.1016/j.virusres.2023.199169. Epub 2023 Jul 4.
3
Identification of SARS CoV-2 Omicron BA.1 and a novel Delta lineage by rapid methods and partial spike protein sequences in Sulaymaniyah Province, Iraq.
Immun Inflamm Dis. 2023 Mar;11(3):e801. doi: 10.1002/iid3.801.
4
Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic.
Healthcare (Basel). 2023 Mar 14;11(6):854. doi: 10.3390/healthcare11060854.
5
Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned?
World J Virol. 2022 Nov 25;11(6):496-501. doi: 10.5501/wjv.v11.i6.496.
6
Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador.
Viruses. 2022 May 28;14(6):1177. doi: 10.3390/v14061177.
7
The Shortcomings of COVID-19 Testing in Ecuador: Time to Incentivize Research and Innovation.
Life (Basel). 2022 Feb 22;12(3):325. doi: 10.3390/life12030325.
本文引用的文献
1
First Report of SARS-CoV-2 Lineage B.1.1.7 (Alpha Variant) in Ecuador, January 2021.
Infect Drug Resist. 2021 Dec 6;14:5183-5188. doi: 10.2147/IDR.S319439. eCollection 2021.
2
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.
3
poreCov-An Easy to Use, Fast, and Robust Workflow for SARS-CoV-2 Genome Reconstruction Nanopore Sequencing.
Front Genet. 2021 Jul 28;12:711437. doi: 10.3389/fgene.2021.711437. eCollection 2021.
4
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.
Vaccines (Basel). 2021 Mar 11;9(3):243. doi: 10.3390/vaccines9030243.
5
COVID-19 in early 2021: current status and looking forward.
Signal Transduct Target Ther. 2021 Mar 8;6(1):114. doi: 10.1038/s41392-021-00527-1.
6
GISAID: Global initiative on sharing all influenza data - from vision to reality.
Euro Surveill. 2017 Mar 30;22(13). doi: 10.2807/1560-7917.ES.2017.22.13.30494.
Zotero 插件